Kobayashi Pharmaceutical Co (FRA:KOY) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KOY Kobayashi Pharmaceutical Co Ltd FRA:KOY
77 GF Score
Price €30.40
GF Value €26.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kobayashi Pharmaceutical Co FRA:KOY +0.66% 77 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:KOY with a GF Score™ of 77/100 and a GF Value™ of €26.16 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kobayashi Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was €0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kobayashi Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kobayashi Pharmaceutical Co was 6.20% per year. The lowest was 1.90% per year. And the median was 4.10% per year.

As of today (2026-09-05), Kobayashi Pharmaceutical Co's current stock price is €30.40. Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kobayashi Pharmaceutical Co was 7.06. The lowest was 2.27. And the median was 4.34.


Kobayashi Pharmaceutical Co  (FRA:KOY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kobayashi Pharmaceutical Co was 7.06. The lowest was 2.27. And the median was 4.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kobayashi Pharmaceutical Co Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.02 13.79 13.00 13.09 12.09

Kobayashi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.90 12.55 12.09 12.11 0.00

FRA:KOY vs PG, CL, EL: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobayashi Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kobayashi Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FRA:KOY
77GF Score
Kobayashi Pharmaceutical Co Ltd FRA:KOY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobayashi Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kobayashi Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Kobayashi Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.099 98.000 4.751
201612 4.663 98.400 5.383
201703 3.229 98.100 3.739
201706 3.726 98.500 4.297
201709 3.867 98.800 4.446
201712 4.649 99.400 5.313
201803 3.262 99.200 3.736
201806 3.832 99.200 4.388
201809 4.166 99.900 4.737
201812 5.123 99.700 5.837
201903 3.195 99.700 3.640
201906 3.933 99.800 4.477
201909 4.523 100.100 5.133
201912 4.975 100.500 5.623
202003 3.432 100.300 3.887
202006 3.619 99.900 4.115
202009 3.998 99.900 4.546
202012 4.606 99.300 5.269
202103 2.993 99.900 3.403
202106 3.547 99.500 4.050
202109 4.008 100.100 4.549
202112 4.743 100.100 5.383
202203 3.229 101.100 3.628
202206 3.529 101.800 3.938
202209 3.924 103.100 4.324
202212 4.753 104.100 5.187
202303 3.074 104.400 3.345
202306 3.444 105.200 3.719
202309 3.787 106.200 4.051
202312 4.611 106.800 4.905
202403 3.014 107.200 3.194
202406 2.901 108.200 3.046
202409 3.504 108.900 3.655
202412 4.269 110.700 4.381
202503 2.724 111.100 2.785
202506 2.939 111.700 2.989
202509 3.335 112.000 3.383
202512 3.957 113.000 3.978
202603 2.471 112.700 2.491
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Kobayashi Pharmaceutical Co (FRA:KOY) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kobayashi Pharmaceutical Co and its competitors.
Is Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kobayashi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Kobayashi Pharmaceutical Co's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kobayashi Pharmaceutical Co and its competitors. Kobayashi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co (FRA:KOY) is currently considered Modestly Overvalued. The stock's GF Value™ is €26.16, compared to a current price of €30.40 — trading 16.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Kobayashi Pharmaceutical Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (FRA:KOY), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kobayashi Pharmaceutical Co (FRA:KOY) Overvalued in 2026?

Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued. The current stock price of €30.40 is trading 16.2% above its estimated GF Value™ of €26.16. GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:KOY:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €26.16 vs. price of €30.40 (16.2% above fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the FRA:KOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kobayashi Pharmaceutical Co Business Description

Other Exchanges 4967:Japan
Address 4-4-10 Doshomachi, KDX Kobayashi Doshomachi Building, Chuo-ku, Osaka, JPN, 541-0045
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
77GF Score

Get the complete analysis for FRA:KOY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.40
Price
€26.16
GF Value